Impact of GLP-1 on Obesity Glucagon-like peptide-1 (GLP-1) receptor agonists, initially designed for type 2 diabetes (T2D), have emerged as a revolutionary treatment for obesity owing to their significant impact on weight reduction and metabolic control
Available online at: (Accessed February 6, 2025)
Appearance scores exhibited a gradual increase in parallel with L-carnitine enrichment, peaking at 15% inclusion (6.66), followed by a modest decline at 20%, suggesting that moderate levels may enhance visual attractiveness, while excessive concentrations could diminish sensory preference (Table 4)
In April 2026, Haryana drug control authorities seized counterfeit Mounjaro injections worth nearly 70 lakh in Gurugram, raising concerns about unsafe manufacturing and storage in the wider supply chain (India Today, April 2026)
The key outcome measures were GSH levels in various body compartments, including blood, erythrocytes, plasma, lymphocytes, and exfoliated buccal mucosal cells
click on the link below To view or add a comment, sign in 7,411 followers